HCA HCA Healthcare, Inc. Common Stock
NYSE · Health Care · SEC EDGAR에서 보기 ↗ 종가 10월 6, 2026 10-K/10-Q 7월 28, 2026HCA 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
HCA 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
막대 세분성은 선택한 기간에 따라 조정됩니다. 막대의 시가/고가/저가/종가를 보려면 차트에 마우스를 올리세요.
HCA Healthcare, Inc. Common Stock 정보 위키백과 회사 개요
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
10년 성과 매출, 순이익, 마진 및 EPS 추세
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
| 지표 | 5년 추세 | HCA | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| P/E (TTM) | 14.55년 평균 ≈13.8 | ≈13.8 | 16.5 | 저평가 | |
| P/S (TTM) | 1.25년 평균 ≈1.2 | ≈1.2 | 1.3 | 저평가 | |
| P/B (MRQ) | -14.25년 평균 ≈-39.2 | ≈-39.2 | · | · | |
| EV / EBITDA | 39.15년 평균 ≈37.3 | ≈37.3 | 19.6 | 고평가 | |
| 주가 / FCF (TTM) | 15.75년 평균 ≈14.6 | ≈14.6 | · | · | |
| 주가 / 현금 흐름 (TTM) | 8.55년 평균 ≈7.9 | ≈7.9 | 9.7 | 저평가 | |
| EV / Revenue (EV / 매출) | 1.85년 평균 ≈1.8 | ≈1.8 | · | · | |
| EV / FCF | 17.95년 평균 ≈21.8 | ≈21.8 | · | · | |
| PEG Ratio (PEG 비율) | ≈0.7 | · | · | · |
동종 기업 중앙값은 지표별로 표준화된 기준으로 계산되며, 이 주식에 표시된 TTM/MRQ 기준과 항상 일치하지 않을 수 있습니다.
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
| 지표 | 5년 추세 | HCA | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| EBITDA Margin (EBITDA 마진) | 4.7%5년 평균 ≈4.8% | ≈4.8% | 11.1% | 약함 | |
| 세전 마진 (TTM) | 12.7%5년 평균 ≈13.6% | ≈13.6% | 9.8% | 최상위권 | |
| 순이익률 (TTM) | 8.8%5년 평균 ≈9.3% | ≈9.3% | 7.3% | 동일 | |
| ROA (TTM) | 11.1%5년 평균 ≈11.2% | ≈11.2% | 6.5% | 최상위권 | |
| ROE (TTM) | -124.0%5년 평균 ≈-963.7% | ≈-963.7% | 19.1% | 약함 |
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
| 지표 | 5년 추세 | HCA | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 (MRQ) | -6.55년 평균 ≈-19.5 | ≈-19.5 | 0.2 | 낮은 부채 | |
| 유동비율 (MRQ) | 1.05년 평균 ≈1.2 | ≈1.2 | 1.2 | 낮은 유동성 | |
| Quick Ratio (당좌 비율) | 0.75년 평균 ≈0.9 | ≈0.9 | 0.9 | 낮은 유동성 | |
| 장기 부채 / 자기 자본 (MRQ) | -6.55년 평균 ≈-18.7 | ≈-18.7 | 0.2 | 낮은 부채 |
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
| 지표 | 5년 추세 | HCA | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Revenue YoY (매출 YoY) | 7.1%5년 평균 ≈8.0% | ≈8.0% | · | · | |
| Revenue CAGR 3Y (매출 CAGR 3년) | 7.9%5년 평균 ≈7.4% | ≈7.4% | · | · | |
| Revenue CAGR 5Y (매출 CAGR 5년) | 8.0% | · | · | · | |
| EPS YoY | 28.8%5년 평균 ≈25.6% | ≈25.6% | · | · | |
| Net Income YoY (순이익 YoY) | 17.8%5년 평균 ≈17.4% | ≈17.4% | · | · | |
| EPS CAGR 3Y (EPS CAGR 3년) | 13.9%5년 평균 ≈11.8% | ≈11.8% | · | · | |
| EPS CAGR 5Y (EPS CAGR 5년) | 21.0% | · | · | · | |
| Net Income CAGR 3Y (순이익 CAGR 3년) | 6.3%5년 평균 ≈4.0% | ≈4.0% | · | · | |
| Net Income CAGR 5Y (순이익 CAGR 5년) | 12.6% | · | · | · |
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
| 지표 | 5년 추세 | HCA | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Asset Turnover (자산 회전율) | 1.35년 평균 ≈1.2 | ≈1.2 | 0.8 | 최상위권 | |
| Receivables Turnover (매출 채권 회전율) | 7.05년 평균 ≈7.1 | ≈7.1 | 8.4 | 약함 | |
| Revenue / Employee (연간 매출액 ÷ 직원 수(yfinance 보고 인원수). 파생 — 저장된 SEC-XBRL 개념이 아님.) | ≈$328.7K | · | · | · |
가치 · ≈ 5년 평균 · 산업 중앙값 · 중앙값 대비 평가
배당금 배당 수익률, 지급 비율, 배당 이력, 5년 CAGR
| 배당락일 | 금액 | 통화 | 수익률 |
|---|---|---|---|
| 9월 16, 2026 | $0.78 | USD | ≈0.71% |
| 6월 16, 2026 | $0.78 | USD | ≈0.76% |
| 3월 17, 2026 | $0.78 | USD | ≈0.58% |
| 12월 15, 2025 | $0.72 | USD | ≈0.60% |
| 9월 16, 2025 | $0.72 | USD | ≈0.71% |
| 6월 16, 2025 | $0.72 | USD | ≈0.75% |
| 3월 17, 2025 | $0.72 | USD | ≈0.82% |
| 12월 13, 2024 | $0.66 | USD | ≈0.84% |
| 9월 16, 2024 | $0.66 | USD | ≈0.64% |
| 6월 14, 2024 | $0.66 | USD | ≈0.75% |
| 3월 14, 2024 | $0.66 | USD | ≈0.76% |
| 12월 13, 2023 | $0.60 | USD | ≈0.89% |
| 9월 14, 2023 | $0.60 | USD | ≈0.90% |
| 6월 15, 2023 | $0.60 | USD | ≈0.81% |
| 3월 16, 2023 | $0.60 | USD | ≈0.90% |
| 12월 13, 2022 | $0.56 | USD | ≈0.92% |
| 9월 15, 2022 | $0.56 | USD | ≈1.0% |
| 6월 15, 2022 | $0.56 | USD | ≈1.1% |
| 3월 16, 2022 | $0.56 | USD | ≈0.75% |
| 12월 13, 2021 | $0.48 | USD | ≈0.90% |
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
| 기간 | 보고서 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|---|
| 2026년 6월 30일 | 7월 23, 2026 | $7.62 | $7.54 | 1.0% |
| 2026년 3월 31일 | $7.15 | $7.21 | -0.85% | |
| 2025년 12월 31일 | $8.14 | $7.53 | 8.0% | |
| 2025년 9월 30일 | $6.96 | $5.77 | 20.6% | |
| 2025년 6월 30일 | $6.83 | $6.31 | 8.2% | |
| 2025년 3월 31일 | $6.45 | $5.84 | 10.5% |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
대차대조표
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
현금 흐름
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
수익성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
유동성 및 지급능력
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
효율성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
주당
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-26.83 | $-10.00 | $-6.68 | $-9.98 | $-3.05 | $1.69 | $-8.30 | $-14.44 | $-19.44 | $-19.71 | |
| Revenue / Share | $315.66 | $269.68 | $235.04 | $204.41 | $178.71 | $149.98 | $147.42 | $131.37 | · | · | |
| Cash Flow / Share | $52.76 | $40.16 | $34.12 | $28.92 | $27.25 | $26.87 | $21.83 | $19.03 | $14.58 | $14.28 | |
| Cash / Share | $4.63 | $7.73 | $3.52 | $3.27 | $4.75 | $5.28 | $1.83 | $1.46 | $2.09 | $1.74 | |
| Dividend / Share | $2.88 | $2.64 | $2.40 | $2.24 | $1.92 | $0.43 | $1.60 | $1.40 | · | · | |
| EPS (TTM) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 |
성장률
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM)
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
손익계산서
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | · | 232,891,000 | 239,173,000 | 246,936,000 | · | 256,763,000 | 261,156,000 | 264,435,000 | · | 271,173,000 | 274,494,000 | 276,910,000 | · | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | · | 236,181,000 | 241,911,000 | 249,440,000 | · | 259,917,000 | 264,071,000 | 268,016,000 | · | 275,424,000 | 278,198,000 | 280,961,000 | · | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
대차대조표
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
현금 흐름
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
수익성
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
유동성 및 지급능력
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
효율성
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
주당
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-30.47 | $-28.32 | · | $-23.21 | $-18.61 | $-14.48 | · | $-8.57 | $-6.17 | $-6.14 | · | $-9.21 | $-8.44 | $-9.04 | · | $-11.87 | |
| Revenue / Share | $90.79 | $84.31 | · | $81.13 | $76.91 | $73.45 | · | $67.28 | $66.24 | $64.69 | · | $58.87 | $57.01 | $55.49 | · | $51.65 | |
| Cash Flow / Share | · | $8.89 | · | · | · | $6.62 | · | · | · | $9.21 | · | · | · | $6.42 | · | · | |
| Cash / Share | $4.65 | $4.22 | · | $4.34 | $3.98 | $4.36 | · | $11.35 | $3.21 | $4.88 | · | $3.31 | $3.16 | $3.05 | · | $3.52 | |
| Dividend / Share | $0.78 | $0.78 | $0.72 | $0.72 | $0.72 | $0.72 | $0.66 | $0.66 | $0.66 | $0.66 | $0.60 | $0.60 | $0.60 | $0.60 | $0.56 | $0.56 | |
| EPS (TTM) | $29.82 | $29.03 | · | $25.90 | $23.82 | $22.52 | · | $22.26 | $21.29 | $20.05 | · | $20.25 | $20.25 | $19.86 | · | $17.61 |
가치 평가 (TTM)
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $78.01B | $76.39B | · | $74.37B | $72.70B | $71.58B | · | $69.62B | $68.35B | $66.72B | · | $63.16B | $61.92B | $60.88B | · | $59.80B | |
| Net Income TTM | $6.84B | $6.79B | · | $6.34B | $5.97B | $5.78B | · | $5.93B | $5.74B | $5.47B | · | $5.72B | $5.77B | $5.73B | · | $5.38B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.1 | 16.3 | · | 16.5 | 16.1 | 15.3 | · | 18.3 | 15.1 | 16.6 | · | 12.1 | 15.0 | 13.3 | · | 10.4 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.2 | 1.2 | · | 1.5 | 1.2 | 1.3 | · | 1.0 | 1.3 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| EV / Revenue | 1.6 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Dividend Yield | 0.80% | 0.65% | · | 0.70% | 0.76% | 0.82% | · | 0.66% | 0.81% | 0.76% | · | 0.99% | 0.79% | 0.89% | · | 1.2% | |
| Earnings Yield | 7.6% | 6.1% | · | 6.1% | 6.2% | 6.5% | · | 5.5% | 6.6% | 6.0% | · | 8.2% | 6.7% | 7.5% | · | 9.6% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · | |
| Annual Payout | $682M | $682M | · | $682M | $685M | $685M | · | $685M | $678M | $671M | · | $657M | $655M | $651M | · | $645M |
최신 기간은 왼쪽에 · null 값은 ·로 표시
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 매출 | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| 순이익 | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| 희석 EPS | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| 유동비율 | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| 당좌 비율 | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 잉여현금흐름 | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
기관 투자자 (13F) 1,474개의 제출자 · $57.2B 전체 · 기준일 2026년 9월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 121 (-64 이전 분기 대비) | 176 (+72 이전 분기 대비) | 458 (-25 이전 분기 대비) | 581 (+4 이전 분기 대비) | -627K |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6,870,392,526 | 14,716,173 | 12.00% | 주식 |
| BlackRock, Inc. | $5,069,973,824 | 13,003,600 | 8.86% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3,954,150,533 | 10,141,708 | 6.91% | 주식 |
| Sanders Capital, LLC | $3,442,060,818 | 8,828,287 | 6.01% | 주식 |
| STATE STREET CORP | $2,912,102,056 | 7,469,035 | 5.09% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $1,835,396,649 | 4,707,473 | 3.21% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $1,423,654,808 | 3,668,008 | 2.49% | 주식 |
| First Eagle Investment Management, LLC | $1,284,907,912 | 3,295,565 | 2.24% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,057,704,509 | 2,712,828 | 1.85% | 주식 |
| MORGAN STANLEY | $1,008,556,857 | 2,586,771 | 1.76% | 주식 |
| GOLDMAN SACHS GROUP INC | $960,811,481 | 2,464,314 | 1.68% | 주식 |
| JPMORGAN CHASE & CO | $896,800,955 | 2,285,832 | 1.57% | 주식 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861,456,107 | 2,209,485 | 1.50% | 주식 |
| NORGES BANK | $836,457,140 | 2,145,367 | 1.46% | 주식 |
| Capital World Investors | $770,864,224 | 1,977,121 | 1.35% | 주식 |
| Capital International Investors | $747,403,041 | 1,916,947 | 1.31% | 주식 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $709,859,997 | 1,500,000 | 1.24% | 주식 |
| NORTHERN TRUST CORP | $666,150,458 | 1,708,560 | 1.16% | 주식 |
| FMR LLC | $636,503,475 | 1,632,520 | 1.11% | 주식 |
| Invesco Ltd. | $596,390,232 | 1,529,637 | 1.04% | 주식 |
| NORDEA INVESTMENT MANAGEMENT AB | $553,702,529 | 1,429,943 | 0.97% | 주식 |
| BARCLAYS PLC | $514,349,127 | 1,319,216 | 0.90% | 주식 |
| JANUS HENDERSON GROUP PLC | $481,486,890 | 1,017,441 | 0.84% | 주식 |
| Crake Asset Management LLP | $449,072,183 | 1,151,792 | 0.78% | 주식 |
| Metropolis Capital Ltd | $430,915,307 | 910,564 | 0.75% | 주식 |
| Darsana Capital Partners LP | $428,879,000 | 1,100,000 | 0.75% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414,565,358 | 1,063,288 | 0.72% | 주식 |
| Legal & General Group Plc | $410,992,402 | 1,054,124 | 0.72% | 주식 |
| FRANKLIN RESOURCES INC | $399,958,688 | 1,025,824 | 0.70% | 주식 |
| Life Cycle Investment Partners Ltd | $355,737,196 | 912,404 | 0.62% | 주식 |
| Bank of New York Mellon Corp | $350,359,895 | 898,612 | 0.61% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $339,685,814 | 871,235 | 0.59% | 주식 |
| ROYAL BANK OF CANADA | $320,194,000 | 821,241 | 0.56% | 주식 |
| LYRICAL ASSET MANAGEMENT LP | $255,015,742 | 654,071 | 0.45% | 주식 |
| BANK OF AMERICA CORP /DE/ | $238,456,934 | 611,601 | 0.42% | 주식 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $237,236,367 | 608,470 | 0.41% | 주식 |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235,649,908 | 604,401 | 0.41% | 주식 |
| PRINCIPAL FINANCIAL GROUP INC | $234,827,401 | 602,290 | 0.41% | 주식 |
| UBS Group AG | $230,953,291 | 592,355 | 0.40% | 주식 |
| National Pension Service | $230,650,346 | 591,578 | 0.40% | 주식 |
| Russell Investments Group, Ltd. | $206,832,565 | 530,340 | 0.36% | 주식 |
| Nuveen, LLC | $199,595,109 | 511,927 | 0.35% | 주식 |
| Gobi Capital LLC | $195,742,325 | 502,045 | 0.34% | 주식 |
| Cryder Capital Partners LLP | $194,561,738 | 499,017 | 0.34% | 주식 |
| Allianz Asset Management GmbH | $181,127,299 | 464,560 | 0.32% | 주식 |
| DEUTSCHE BANK AG\ | $175,985,429 | 451,372 | 0.31% | 주식 |
| Swiss National Bank | $172,097,446 | 441,400 | 0.30% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $172,079,393 | 441,313 | 0.30% | 주식 |
| AustralianSuper Pty Ltd | $159,635,782 | 409,438 | 0.28% | 주식 |
| HSBC HOLDINGS PLC | $158,555,065 | 406,750 | 0.28% | 주식 |
행동주의자 및 5% 이상 소유자 4 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 2026년 2월 10일 | 31.60% | 최초 제출 | · | SEC |
| 2006년 11월 22일 | · | 최초 제출 | · | SEC | |
| Merrill Lynch Bank USA | 2006년 9월 11일 | · | 최초 제출 | · | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 2006년 8월 4일 | · | 최초 제출 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
회사 내부자 92 명의 내부자 · 54 임원 · 31 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 2026년 2월 10일 F | 64,842 | 0 | 7 | $-21,483,290 |
| O'Boyle Michael P | President & CEO - Parallon | 2013년 2월 26일 A | 21,429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 2026년 5월 7일 G | 46,576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 2024년 2월 16일 F | 22,251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 2005년 7월 1일 F | 13,865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 2024년 11월 12일 M | 6,843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 2024년 7월 31일 M | 27,008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 2024년 2월 16일 F | 17,936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 2022년 11월 11일 M | 202,443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 2022년 11월 11일 S | 30,807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 2012년 12월 31일 A | 335,657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 2011년 11월 2일 M | 144,714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 2006년 7월 26일 A | 62,173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 2005년 10월 27일 A | 26,154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 2004년 10월 31일 D | 9,029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 2004년 5월 7일 D | 24,177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 2026년 2월 10일 F | 23,062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 2026년 8월 26일 J | 0 | 0 | 2 | $-2,747,520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 2026년 2월 11일 S | 11,993 | 0 | 2 | $-4,126,932 |
| Christopher F. Wyatt | SVP & Controller | 2026년 2월 11일 S | 44,379 | 0 | 1 | $-2,020,000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 2026년 2월 10일 F | 10,407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 2026년 2월 10일 F | 32,080 | 0 | 1 | $-747,135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 2025년 2월 13일 F | 11,113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 2024년 11월 14일 S | 9,454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 2024년 11월 12일 M | 52,702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 2024년 8월 5일 G | 18,526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 2024년 7월 29일 S | 3,510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 2024년 7월 25일 S | 17,755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 2024년 5월 9일 S | 5,185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 2024년 3월 18일 M | 1,576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 2023년 4월 12일 M | 24,643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 2021년 11월 9일 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 2021년 5월 5일 S | 50,062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 2021년 2월 18일 F | 5,578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 2021년 2월 18일 F | 10,122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 2019년 5월 1일 A | 194,145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 2019년 2월 25일 M | 84,157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 2019년 2월 25일 M | 881,823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 2018년 2월 25일 M | 7,003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 2018년 2월 25일 M | 35,546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 2018년 2월 25일 M | 65,199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 2017년 5월 23일 M | 26,378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 2016년 11월 7일 M | 110,167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 2016년 2월 25일 A | 51,965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 2012년 5월 16일 M | 299,030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 2009년 10월 6일 A | 188,340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 2009년 2월 27일 M | 13,092 | 0 | 0 | $0 |
| Patricia T Lindler | SVP - Government Programs | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Rosalyn S Elton | SVP-Operations Finance | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Frank M Houser MD | SVP-Quality & Medical Director | 2006년 7월 26일 A | 46,145 | 0 | 0 | $0 |
| James A Fitzgerald JR | SVP-Supply Chain Operations | 2006년 1월 29일 F | 20,674 | 0 | 0 | $0 |
| Andrea B Smith | 이사 | 2026년 4월 28일 A | 4,666 | 0 | 0 | $0 |
| William R Frist | 이사 | 2026년 4월 28일 A | 13,740 | 0 | 0 | $0 |
| Wayne Joseph Riley | 이사 | 2026년 4월 28일 A | 15,029 | 0 | 0 | $0 |
| Hugh F Johnston | 이사 | 2026년 4월 28일 A | 4,475 | 0 | 0 | $0 |
| Thomas F Frist III | 이사 | 2026년 4월 28일 A | 15,858 | 0 | 0 | $0 |
| Michael W Michelson | 이사 | 2026년 4월 28일 A | 12,576 | 0 | 0 | $0 |
| Nancy Ann Deparle | 이사 | 2026년 4월 28일 A | 21,910 | 0 | 0 | $0 |
| John Chidsey | 이사 | 2026년 4월 28일 A | 1,305 | 0 | 0 | $0 |
| Robert J Dennis | 이사 | 2025년 4월 29일 A | 26,601 | 0 | 0 | $0 |
| Meg Crofton | 이사 | 2024년 4월 29일 A | 6,331 | 0 | 0 | $0 |
| Charles O Holliday JR | 이사 | 2022년 4월 25일 A | 18,955 | 0 | 0 | $0 |
| Geoffrey G Meyers | 이사 | 2019년 5월 1일 A | 39,153 | 0 | 0 | $0 |
| John W Rowe | 이사 | 2019년 5월 1일 A | 30,388 | 0 | 0 | $0 |
| Ann H Lamont | 이사 | 2018년 5월 2일 A | 17,661 | 0 | 0 | $0 |
| Jay O Light | 이사 | 2017년 5월 3일 A | 30,953 | 0 | 0 | $0 |
| Stephen G Pagliuca | 이사 | 2014년 12월 5일 D | 7,612,921 | 0 | 0 | $0 |
| Christopher R Gordon | 이사 | 2013년 11월 1일 D | 30,003,156 | 0 | 0 | $0 |
| John Connaughton | 이사 | 2013년 11월 1일 D | 30,003,156 | 0 | 0 | $0 |
| John H Mcarthur | 이사 | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Kent C Nelson | 이사 | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Magdalena Averhoff MD | 이사 | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Glenda A Hatchett | 이사 | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Frederick W Gluck | 이사 | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Harold T Shapiro | 이사 | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Michael C Armstrong | 이사 | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Martin Feldstein | 이사 | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Michael T Long | 이사 | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| ROYAL FRANK S | 이사 | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Patricia F Elcan | 10% 소유주 | 2026년 2월 6일 J | 36,557,141 | 0 | 0 | $0 |
| Frisco Holding II | 10% 소유주 | 2026년 2월 6일 J | 36,557,141 | 0 | 0 | $0 |
| HERCULES HOLDING II, LLC | 10% 소유주 | 2026년 2월 6일 J | 32,282,889 | 0 | 0 | $0 |
| Thomas F Frist JR | 10% 소유주 | 2026년 2월 6일 J | 36,557,141 | 0 | 0 | $0 |
| Patricia C Frist | 10% 소유주 | 2018년 2월 20일 G | 0 | 0 | 0 | $0 |
| KKR PEI GP LTD | 10% 소유주 | 2014년 4월 1일 J | 0 | 0 | 0 | $0 |
| Jonathan B Perlin | · | 2021년 8월 2일 S | 44,348 | 0 | 0 | $0 |
| Juan Vallarino | · | 2016년 5월 9일 M | 61,036 | 0 | 0 | $0 |
| Richard M Bracken | · | 2014년 12월 31일 F | 82,499 | 0 | 0 | $0 |
| BANK OF AMERICA CORP /DE/ | · | 2012년 11월 6일 S | 2,652,364 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
ETF 보유 현황 141 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| BUL · Pacer Funds Trust | 5.07% | 16,545 NS | 2026년 7월 31일 | N-PORT |
| IHF · iShares Trust | 4.75% | 147,977 SH | 2026년 9월 11일 | 일간 |
| STNC · Hennessy Funds Trust | 3.17% | 7,315 NS | 2026년 7월 31일 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2.47% | 97,151 SH | 2026년 10월 5일 | 일간 |
| COWZ · Pacer Funds Trust | 2.07% | 960,711 NS | 2026년 7월 31일 | N-PORT |
| WLTG · ETF Opportunities Trust | 2.06% | 3,942 NS | 2026년 7월 31일 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.67% | 34,181 SH | 2026년 10월 5일 | 일간 |
| RPG · Invesco Exchange-Traded Fund Trust | 1.27% | 58,310 SH | 2026년 10월 5일 | 일간 |
| FLAG · Global X Funds | 1.14% | 48 NS | 2026년 7월 31일 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1.03% | 6,909 NS | 2026년 7월 31일 | N-PORT |
| IYH · iShares Trust | 1.01% | 87,417 SH | 2026년 9월 11일 | 일간 |
| SRHQ · Elevation Series Trust | 0.94% | 4,938 NS | 2026년 7월 31일 | N-PORT |
| NEAR · iShares U.S. ETF Trust | 0.92% | 48,109,000 SH | 2026년 9월 11일 | 일간 |
| FHLC · FIDELITY COVINGTON TRUST | 0.91% | 74,445 NS | 2026년 7월 31일 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.90% | 470,451 SH | 2026년 8월 19일 | 일간 |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.87% | 22,725 NS | 2026년 7월 31일 | N-PORT |
| DIVB · iShares Trust | 0.87% | 42,100 SH | 2026년 9월 11일 | 일간 |
| NFRA · FlexShares Trust | 0.84% | 62,628 NS | 2026년 7월 31일 | N-PORT |
| IXJ · iShares Trust | 0.83% | 81,708 SH | 2026년 9월 11일 | 일간 |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.80% | 2,483 SH | 2026년 10월 5일 | 일간 |
| QUVU · Hartford Funds Exchange-Traded Trust | 0.79% | 3,522 NS | 2026년 7월 31일 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.78% | 23,458,000 | 2026년 10월 5일 | 일간 |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0.74% | 25,787,000 | 2026년 10월 5일 | 일간 |
| CURE · Direxion Shares ETF Trust | 0.72% | 3,056 NS | 2026년 7월 31일 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.67% | 12,075 SH | 2026년 8월 19일 | 일간 |
| LGDX · Tidal Trust III | 0.66% | 2,345 NS | 2026년 7월 31일 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.55% | 11,876 SH | 2026년 8월 19일 | 일간 |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0.50% | 22,854,000 | 2026년 10월 5일 | 일간 |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.46% | 7,404 NS | 2026년 7월 31일 | N-PORT |
| WLDR · Two Roads Shared Trust | 0.43% | 964 NS | 2026년 7월 31일 | N-PORT |
| ROUS · Lattice Strategies Trust | 0.42% | 7,289 NS | 2026년 7월 31일 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.40% | 92,347 SH | 2026년 10월 5일 | 일간 |
| QLC · FlexShares Trust | 0.39% | 9,856 NS | 2026년 7월 31일 | N-PORT |
| XOEF · iShares Trust | 0.37% | 194 SH | 2026년 9월 11일 | 일간 |
| GSY · Invesco Actively Managed Exchange-T… | 0.36% | 14,000,000 | 2026년 10월 5일 | 일간 |
| UPSD · ETF Series Solutions | 0.33% | 972 NS | 2026년 7월 31일 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0.33% | 9,324,000 | 2026년 10월 5일 | 일간 |
| MGV · VANGUARD WORLD FUND | 0.29% | 97,604 SH | 2026년 8월 19일 | 일간 |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.28% | 390,000 | 2026년 10월 2일 | 일간 |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.28% | 3,186 NS | 2026년 7월 31일 | N-PORT |
| USXF · iShares Trust | 0.26% | 9,226 SH | 2026년 9월 11일 | 일간 |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.26% | 5,813 SH | 2026년 10월 5일 | 일간 |
| IWX · iShares Trust | 0.23% | 21,535 SH | 2026년 9월 11일 | 일간 |
| VTV · VANGUARD INDEX FUNDS | 0.23% | 1,475,731 SH | 2026년 8월 19일 | 일간 |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0.23% | 14,235 NS | 2026년 7월 31일 | N-PORT |
| MPLY · Strategy Shares | 0.22% | 87 NS | 2026년 7월 31일 | N-PORT |
| EUSA · iShares, Inc. | 0.21% | 9,589 SH | 2026년 9월 11일 | 일간 |
| RSP · Invesco Exchange-Traded Fund Trust | 0.21% | 461,214 SH | 2026년 10월 5일 | 일간 |
| FTC · First Trust Exchange-Traded AlphaDE… | 0.20% | 6,420 NS | 2026년 7월 31일 | N-PORT |
| SIZE · iShares Trust | 0.19% | 1,920 SH | 2026년 9월 11일 | 일간 |
| DYNF · BlackRock ETF Trust | 0.19% | 183,934 SH | 2026년 9월 11일 | 일간 |
| VMAX · Lattice Strategies Trust | 0.19% | 228 NS | 2026년 7월 31일 | N-PORT |
| DSI · iShares Trust | 0.19% | 23,734 SH | 2026년 9월 11일 | 일간 |
| ILCV · iShares Trust | 0.18% | 5,870 SH | 2026년 9월 10일 | 일간 |
| IVW · iShares Trust | 0.18% | 331,185 SH | 2026년 9월 11일 | 일간 |
| IUSG · iShares Trust | 0.17% | 136,713 SH | 2026년 9월 11일 | 일간 |
| VOOG · VANGUARD ADMIRAL FUNDS | 0.17% | 115,334 SH | 2026년 8월 19일 | 일간 |
| IWD · iShares Trust | 0.17% | 332,035 SH | 2026년 9월 11일 | 일간 |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.16% | 90,157 SH | 2026년 8월 19일 | 일간 |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.16% | 17,773 SH | 2026년 10월 5일 | 일간 |
| USMV · iShares Trust | 0.16% | 89,855 SH | 2026년 9월 11일 | 일간 |
| ACWV · iShares, Inc. | 0.15% | 11,903 SH | 2026년 9월 11일 | 일간 |
| EGLE · Global X Funds | 0.15% | 8 NS | 2026년 7월 31일 | N-PORT |
| GLBL · Pacer Funds Trust | 0.15% | 4 NS | 2026년 7월 31일 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.14% | 33,331 SH | 2026년 10월 5일 | 일간 |
| VOXP · Advisors Series Trust | 0.13% | 18 NS | 2026년 7월 31일 | N-PORT |
| VRIG · Invesco Actively Managed Exchange-T… | 0.12% | 2,250,000 | 2026년 10월 1일 | 일간 |
| TOPC · iShares Trust | 0.12% | 95 SH | 2026년 9월 11일 | 일간 |
| DGRO · iShares Trust | 0.12% | 120,741 SH | 2026년 9월 11일 | 일간 |
| XVV · iShares Trust | 0.11% | 1,790 SH | 2026년 9월 11일 | 일간 |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.11% | 4,428 SH | 2026년 10월 5일 | 일간 |
| IWL · iShares Trust | 0.11% | 5,786 SH | 2026년 9월 11일 | 일간 |
| MGC · VANGUARD WORLD FUND | 0.11% | 31,176 SH | 2026년 8월 19일 | 일간 |
| ACIO · ETF Series Solutions | 0.11% | 6,205 NS | 2026년 7월 31일 | N-PORT |
| EVUS · iShares Trust | 0.10% | 934 SH | 2026년 9월 11일 | 일간 |
| ADME · ETF Series Solutions | 0.10% | 751 NS | 2026년 7월 31일 | N-PORT |
| XRMI · Global X Funds | 0.10% | 126 NS | 2026년 7월 31일 | N-PORT |
| XCLR · Global X Funds | 0.10% | 9 NS | 2026년 7월 31일 | N-PORT |
| XYLD · Global X Funds | 0.10% | 8,148 NS | 2026년 7월 31일 | N-PORT |
| XTR · Global X Funds | 0.10% | 12 NS | 2026년 7월 31일 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0.10% | 13,621 NS | 2026년 7월 31일 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.10% | 25,167 SH | 2026년 10월 5일 | 일간 |
| VV · VANGUARD INDEX FUNDS | 0.10% | 181,364 SH | 2026년 8월 19일 | 일간 |
| ESGV · VANGUARD WORLD FUND | 0.10% | 33,758 SH | 2026년 8월 19일 | 일간 |
| IVV · iShares Trust | 0.10% | 1,957,485 SH | 2026년 9월 11일 | 일간 |
| PTLC · Pacer Funds Trust | 0.10% | 7,919 NS | 2026년 7월 31일 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.10% | 1,395 NS | 2026년 7월 31일 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0.10% | 877 SH | 2026년 10월 5일 | 일간 |
| ILCB · iShares Trust | 0.10% | 2,915 SH | 2026년 9월 11일 | 일간 |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.10% | 1,794 SH | 2026년 10월 2일 | 일간 |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.09% | 20,766 NS | 2026년 7월 31일 | N-PORT |
| IYY · iShares Trust | 0.09% | 6,693 SH | 2026년 9월 11일 | 일간 |
| VOTE · TCW ETF Trust | 0.09% | 2,545 NS | 2026년 7월 31일 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.09% | 3,614 NS | 2026년 7월 31일 | N-PORT |
| XYLG · Global X Funds | 0.09% | 147 NS | 2026년 7월 31일 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.09% | 46,791 NS | 2026년 7월 31일 | N-PORT |
| IWB · iShares Trust | 0.09% | 103,721 SH | 2026년 9월 11일 | 일간 |
| VOO · VANGUARD INDEX FUNDS | 0.09% | 4,034,357 SH | 2026년 8월 19일 | 일간 |
| TOV · EA Series Trust | 0.09% | 607 NS | 2026년 7월 31일 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.09% | 586 NS | 2026년 7월 31일 | N-PORT |
| ITOT · iShares Trust | 0.09% | 202,387 SH | 2026년 9월 11일 | 일간 |
| ACVF · ETF Opportunities Trust | 0.09% | 337 NS | 2026년 7월 31일 | N-PORT |
| GTOS · Invesco Actively Managed Exchange-T… | 0.09% | 104,000 | 2026년 10월 5일 | 일간 |
| QDPL · Pacer Funds Trust | 0.09% | 3,708 NS | 2026년 7월 31일 | N-PORT |
| IWV · iShares Trust | 0.09% | 41,034 SH | 2026년 9월 11일 | 일간 |
| DFAU · Dimensional ETF Trust | 0.08% | 25,516 NS | 2026년 7월 31일 | N-PORT |
| CRBN · iShares Trust | 0.08% | 2,269 SH | 2026년 9월 11일 | 일간 |
| TOK · iShares Trust | 0.08% | 451 SH | 2026년 9월 11일 | 일간 |
| VTI · VANGUARD INDEX FUNDS | 0.08% | 4,930,930 SH | 2026년 8월 19일 | 일간 |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.08% | 24,633 SH | 2026년 8월 19일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.08% | 12,577 SH | 2026년 8월 19일 | 일간 |
| PHDG · Invesco Actively Managed Exchange-T… | 0.08% | 116 SH | 2026년 10월 5일 | 일간 |
| HCMT · Direxion Shares ETF Trust | 0.08% | 1,081 NS | 2026년 7월 31일 | N-PORT |
| TILT · FlexShares Trust | 0.08% | 4,108 NS | 2026년 7월 31일 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0.07% | 12,141 NS | 2026년 7월 31일 | N-PORT |
| URTH · iShares, Inc. | 0.07% | 14,079 SH | 2026년 9월 11일 | 일간 |
| ACWI · iShares Trust | 0.06% | 50,294 SH | 2026년 9월 11일 | 일간 |
| HDUS · Lattice Strategies Trust | 0.05% | 275 NS | 2026년 7월 31일 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.05% | 125,729 SH | 2026년 8월 19일 | 일간 |
| DCOR · Dimensional ETF Trust | 0.05% | 3,816 NS | 2026년 7월 31일 | N-PORT |
| GLOF · iShares Trust | 0.04% | 202 SH | 2026년 9월 11일 | 일간 |
| DUHP · Dimensional ETF Trust | 0.04% | 10,761 NS | 2026년 7월 31일 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.02% | 28,662 NS | 2026년 7월 31일 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.02% | 1,127 NS | 2026년 7월 31일 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.01% | 99 NS | 2026년 7월 31일 | N-PORT |
| GTO · Invesco Actively Managed Exchange-T… | 0.00% | 42,000 | 2026년 9월 30일 | 일간 |
| CBLS · Elevation Series Trust | -1.12% | -1,546 NS | 2026년 7월 31일 | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 2026년 7월 15일 | 일간 |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 2026년 7월 15일 | 일간 |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 2026년 7월 15일 | 일간 |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 2026년 7월 30일 | 일간 |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 2026년 7월 30일 | 일간 |
| VCEB · VANGUARD WORLD FUND | · | · | 2026년 7월 30일 | 일간 |
HCA 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
12개월 목표 주가
22 명의 애널리스트 · 2026-10-05평균 목표 $454.23 +5.1%
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
회계연도 기준, 각 회사의 마지막 회계연도 말 종가 기준 가격입니다.
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | · |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | · |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | · |
| UHS | · | 9.4 | 9.7% | 8.6% | 21.4% | · |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | · |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | · |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | · |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | · |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | · |
최신 뉴스 이 회사 관련 최근 헤드라인
트레이딩 시그널 진입 가격 및 위험/보상 비율을 포함한 최근 매수/매도 신호
현재 열린 신호가 없습니다 — 카드가 채워지지 않았으며, 이는 정직한 것입니다.
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요. 상단의 전체 기본 정보에서 원하는 행 옆의 +를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.